Targovax receives Fast-Track designation for ONCOS-102
· The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma · Fast-Track opens the potential for expedited development and review with the US FDA Oslo, Norway 15 February 2021 – Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA. The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and